Patent: 10,280,208
Summary for Patent: 10,280,208
| Title: | TMIGD2 and its derivatives as blockers or binders of cancer-expressed HHLA2 for immunotherapies |
| Abstract: | Provided are methods of treating an HHLA2-bearing tumor in a subject with a fusion protein comprising an IgV-like domain of a TMIGD2 sufficient to treat the HHLA2-bearing tumor. A fusion protein comprising an IgV-like domain of a TMIGD2 and related compositions and encoding nucleic acids are also provided. |
| Inventor(s): | Zang; Xingxing (New York, NY), Chinai; Jordan M. (Bronx, NY), Janakiram; Murali (Brooklyn, NY), Almo; Steven C. (Pelham, NY), Fiser; Andras (New York, NY) |
| Assignee: | Albert Einstein College of Medicine (Bronx, NY) |
| Application Number: | 15/300,294 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,280,208
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Csl Behring Ag | CARIMUNE, CARIMUNE NF, PANGLOBULIN, SANDOGLOBULIN | immune globulin intravenous (human) | For Injection | 102367 | July 27, 2000 | 10,280,208 | 2035-04-24 |
| Csl Behring Ag | PRIVIGEN | immune globulin intravenous (human), 10% liquid | Injection | 125201 | July 26, 2007 | 10,280,208 | 2035-04-24 |
| Csl Behring Ag | PRIVIGEN | immune globulin intravenous (human), 10% liquid | Injection | 125201 | October 2, 2009 | 10,280,208 | 2035-04-24 |
| Csl Behring Ag | PRIVIGEN | immune globulin intravenous (human), 10% liquid | Injection | 125201 | February 7, 2013 | 10,280,208 | 2035-04-24 |
| Bio Products Laboratory Limited | GAMMAPLEX | immune globulin intravenous (human) | Injection | 125329 | September 17, 2009 | 10,280,208 | 2035-04-24 |
| Bio Products Laboratory Limited | GAMMAPLEX | immune globulin intravenous (human) | Injection | 125329 | February 7, 2014 | 10,280,208 | 2035-04-24 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
